(주)셀렉스라이프사이언스

News

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

[ENG] 보도자료

Science Advances highlights the 2nd Proof of Concept study of EXPLOR®

페이지 정보

  • 작성자 : ILIAS Biologics
  • 작성일 : 21-02-03 17:38
  • 조회 : 335회

본문

 

22 Jan 2021


Science Advances highlights the 2nd Proof of Concept study of EXPLOR® 

 

Our latest publication in Science Advances highlights a novel approach that can potentially save millions of lives of mothers and their babies with engineered exosome treatment. We are excited to present the discovery of a potential breakthrough in treating preterm birth that's still a major cause of infant death all over the world. This is the 2nd Proof of Concept study result that showed the expandability of our platform technology, ​EXPLOR®.

 

Chulhee Choi, CEO and CSO of ILIAS Biologics, Inc. said, “the study result suggests the possibility of the safe and effective treatment to prevent preterm birth by solving the problem of current medications─that cannot cross the placental barrier─with EXPLOR® technology and proves the enormous expandability of exosome-based treatment​.” 

 

Publication (Science Advance)

Press release (PR newswire)

 

개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기